Independent Stockholm3 screening study selected as Best Oncology Abstract at EAU26
Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
An independent study evaluating the use of the Stockholm3 test within Sweden’s organized prostate cancer testing (OPT) program has been awarded Best Oncology Abstract at the Annual European Association of Urology (EAU) Congress, one of the world’s largest scientific meetings in urology, in London.
The study was conducted by investigators within the OPT program, Sweden’s national initiative designed to evaluate organized prostate cancer screening strategies. The research assessed the impact of incorporating Stockholm3 as part of a risk-stratified screening pathway in a population-based program.
Results presented at EAU demonstrated that integrating Stockholm3 into the screening pathway substantially reduced the number of men referred for MRI and biopsy, highlighting the potential of risk-adapted screening approaches to improve efficiency while maintaining detection of clinically significant prostate cancer.[1]
"Organized prostate cancer screening programs must balance early detection with the burden of unnecessary diagnostic procedures," said Ugo Falagario, Urologist and Assistant Professor at the Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy and first author of the study.
“Our findings demonstrate that it is possible to integrate an advanced blood-based risk test into an organized prostate cancer testing program while reducing the burden on healthcare resources. This is important both for patients and for the sustainability of healthcare systems,” says Anna Lantz, Associate Professor at the Department of Molecular Medicine and Surgery and consultant urologist at Karolinska University Hospital, who led the study.
The study (N=13,901) evaluated outcomes among men participating in the OPT screening program, representing a real-world implementation of organized prostate cancer testing. The findings add to the growing body of evidence supporting risk-stratified prostate cancer screening strategies that combine biomarkers with imaging and clinical assessment.
“This recognition at EAU underscores the growing interest in more sophisticated screening strategies beyond PSA alone,” said Martin Steinberg, CEO of A3P Biomedical, developer of Stockholm3. “Independent studies such as this provide important validation of how biomarker-driven approaches can improve prostate cancer screening programs.”
[1] Falagario U.G, Akre O., Carlsson S. et al. Stockholm3 test performance for reducing MRI in Organised Prostate Cancer Testing (OPT). EAU26 - 41st Annual European Association of Urology (EAU) Congress; March 13-16, London, UK.